Q/C Technologies, Inc. (QCLS) Spending and interest coverage
- R&D / revenue · 12 months: Value (m); Formula and calculation Research and development expense / revenue. Period ending 2026-06-30..
- Stock-based compensation / revenue · 12 months: Value (m); Formula and calculation Share-based compensation / revenue. Period ending 2026-06-30..
- Interest coverage · 12 months: Value (m); Formula and calculation Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified..
Spending and interest coverage
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| R&D / revenue · 12 months | (m) | Research and development expense / revenue. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Stock-based compensation / revenue · 12 months | (m) | Share-based compensation / revenue. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Interest coverage · 12 months | (m) | Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Research and development spending | 1.80M USD | Research and Development Expense |
| Revenue | (m) | Revenue from Contract with Customer, Excluding Assessed Tax |
| Stock-based compensation | 4.42M USD | Share-based Payment Arrangement, Noncash Expense |
| Operating income | -14.15M USD | Operating Income (Loss) |
| Interest expense · reported / estimated | (m) | · Estimated expense assumptions |
Latest interest expense basis: (m). Estimated values carry *; expand each history row’s basis for its dated balances and rate assumptions.
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Research and development spending (USD) | Revenue (USD) | Stock-based compensation (USD) | Operating income (USD) | Interest expense · reported / estimated (USD) | R&D / revenue | SBC / revenue | Interest coverage | Interest expense basis |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $1.80M | (m) | $4.42M | $-14.15M | (m) | (m) | (m) | (m) | (m) |
| 2026-03-31 | $2.44M | (m) | $2.15M | $-9.23M | (m) | (m) | (m) | (m) | (m) |
| 2025-12-31 | $3.47M | (m) | $2.17M | $-9.85M | (m) | (m) | (m) | (m) | (m) |
| 2025-09-30 | $3.91M | (m) | $272.83K | $-8.32M | (m) | (m) | (m) | (m) | (m) |
| 2025-06-30 | $4.26M | (m) | $289.77K | $-8.36M | (m) | (m) | (m) | (m) | (m) |
| 2025-03-31 | $3.79M | (m) | $624.54K | $-9.86M | (m) | (m) | (m) | (m) | (m) |
| 2024-12-31 | $3.44M | (m) | $1.06M | $-10.17M | (m) | (m) | (m) | (m) | (m) |
| 2024-09-30 | $5.27M | (m) | $1.68M | $-12.89M | (m) | (m) | (m) | (m) | (m) |
| 2024-06-30 | $6.47M | (m) | $2.26M | $-14.91M | (m) | (m) | (m) | (m) | (m) |
| 2024-03-31 | $8.30M | (m) | $3.50M | $-17.32M | (m) | (m) | (m) | (m) | (m) |
| 2023-12-31 | $7.87M | (m) | $3.05M | $-17.12M | (m) | (m) | (m) | (m) | (m) |
| 2023-09-30 | $7.38M | (m) | $2.46M | $-16.02M | (m) | (m) | (m) | (m) | (m) |
| 2023-06-30 | $7.27M | (m) | $2.21M | $-15.89M | (m) | (m) | (m) | (m) | (m) |
| 2023-03-31 | $7.21M | (m) | $667.26K | $-13.75M | (m) | (m) | (m) | (m) | (m) |
| 2022-12-31 | $9.07M | (m) | $695.19K | $-15.28M | (m) | (m) | (m) | (m) | (m) |
| 2022-09-30 | $7.32M | (m) | (m) | $-14.51M | (m) | (m) | (m) | (m) | (m) |
| 2022-06-30 | $8.53M | (m) | (m) | $-15.21M | (m) | (m) | (m) | (m) | (m) |
| 2022-03-31 | $8.02M | (m) | (m) | $-29.84M | (m) | (m) | (m) | (m) | (m) |
| 2021-12-31 | $6.75M | (m) | (m) | $-28.81M | (m) | (m) | (m) | (m) | (m) |
| 2021-09-30 | (m) | (m) | (m) | $-32.86M | (m) | (m) | (m) | (m) | (m) |
| 2021-06-30 | (m) | (m) | (m) | $-31.58M | (m) | (m) | (m) | (m) | (m) |
| 2021-03-31 | (m) | (m) | (m) | $-10.23M | (m) | (m) | (m) | (m) | (m) |
| 2020-12-31 | $7.96M | (m) | (m) | $-12.29M | (m) | (m) | (m) | (m) | (m) |
| 2020-09-30 | $6.21M | (m) | (m) | $-10.31M | (m) | (m) | (m) | (m) | (m) |
| 2020-06-30 | $4.53M | $862.03K | (m) | $-9.39M | (m) | 525.12% | (m) | (m) | (m) |
| 2020-03-31 | $2.67M | $1.33M | (m) | $-6.55M | (m) | 201.10% | (m) | (m) | (m) |
| 2019-12-31 | $276.79K | $1.58M | $10.80K | $-3.95M | (m) | 17.55% | 0.68% | (m) | (m) |
| 2019-09-30 | $410.09K | $1.78M | (m) | $-5.56M | (m) | 23.08% | (m) | (m) | (m) |
| 2019-06-30 | $513.46K | $1.91M | (m) | $-7.82M | (m) | 26.84% | (m) | (m) | (m) |
| 2019-03-31 | $711.67K | $1.98M | (m) | $-9.11M | (m) | 36.03% | (m) | (m) | (m) |
| 2018-12-31 | $1.06M | $1.67M | (m) | $-10.06M | (m) | 63.84% | (m) | (m) | (m) |
| 2018-09-30 | $1.11M | $2.32M | $2.56K | $-10.38M | (m) | 47.88% | 0.11% | (m) | (m) |
| 2018-06-30 | $1.24M | $2.44M | $12.54K | $-8.44M | (m) | 50.86% | 0.51% | (m) | (m) |
| 2018-04-11 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2018-03-31 | $1.28M | $2.99M | $17.13K | $-7.15M | (m) | 42.82% | 0.57% | (m) | (m) |
| 2017-12-31 | $1.24M | $3.93M | $19.46K | $-5.05M | (m) | 31.49% | 0.50% | (m) | (m) |
| 2017-09-30 | $1.19M | $3.19M | $21.83K | $-4.31M | (m) | 37.12% | 0.68% | (m) | (m) |
| 2017-06-30 | $1.14M | $3.13M | (m) | $-2.83M | (m) | 36.50% | (m) | (m) | (m) |
| 2017-03-31 | $1.17M | $2.89M | (m) | $-3.17M | (m) | 40.62% | (m) | (m) | (m) |
| 2016-12-31 | $1.19M | $2.96M | $51.65K | $-3.33M | (m) | 40.15% | 1.74% | (m) | (m) |
| 2016-09-30 | $1.34M | $2.78M | (m) | $-6.09M | (m) | 48.13% | (m) | (m) | (m) |
| 2016-06-30 | $1.41M | $2.33M | (m) | $-8.74M | (m) | 60.38% | (m) | (m) | (m) |
| 2016-03-31 | $1.46M | $2.34M | (m) | $-9.84M | (m) | 62.51% | (m) | (m) | (m) |
| 2015-12-31 | $1.41M | $2.12M | (m) | $-9.68M | (m) | 66.52% | (m) | (m) | (m) |
| 2015-09-30 | $1.23M | $3.09M | (m) | $-6.76M | (m) | 39.87% | (m) | (m) | (m) |
| 2015-06-30 | $1.10M | $3.38M | (m) | $-5.55M | (m) | 32.50% | (m) | (m) | (m) |
| 2015-03-31 | $968.34K | $3.76M | (m) | $-3.95M | (m) | 25.73% | (m) | (m) | (m) |
| 2014-12-31 | $916.31K | $4.43M | $549.60K | $-3.20M | (m) | 20.70% | 12.41% | (m) | (m) |
| 2014-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2014-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2014-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2013-12-31 | $1.01M | $3.58M | (m) | $-1.81M | (m) | 28.14% | (m) | (m) | (m) |
| 2013-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2013-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2013-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cardio Diagnostics Holdings, Inc. (CDIO) | United States | $0.006B | |
| BIOMERICA INC (BMRA) | United States | $0.011B | |
| VOLITIONRX LTD (VNRX) | $0.003B | -0.64 | |
| IMMUCELL CORP /DE/ (ICCC) | United States | $0.091B | 116.10 |
| Insight Molecular Diagnostics Inc. (IMDX) | United States | $0.129B | -3.90 |
| MYRIAD GENETICS INC (MYGN) | United States | $0.397B | -4.84 |
| Alpha Teknova, Inc. (TKNO) | United States | $0.500B | -18.12 |
| QuidelOrtho Corp (QDEL) | United States | $0.733B | -0.90 |
| ACHIEVE LIFE SCIENCES, INC. (ACHV) | United States | $0.806B | -5.88 |
| Intellia Therapeutics, Inc. (NTLA) | United States | $1.705B | -5.92 |